Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Santarus, Inc. (NASDAQ:SNTS) today announced that on December 20, 2013 it filed an amendment (the “Amendment”) to its Solicitation/Recommendation Statement on Schedule 14D-9 (the “Schedule...
G-III Apparel Group Set to Join the S&P SmallCap 600 PR Newswire NEW YORK, Dec. 23, 2013 NEW YORK, Dec. 23, 2013 /PRNewswire/ -- G-III Apparel Group Ltd. (NASD:GIII) will replace Santarus...
Santarus, Inc. (NASDAQ: SNTS) today announced that it has begun patient enrollment in a multicenter, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose...
Morgan & Morgan Announces the Investigation of Santarus, Inc. PR Newswire NEW YORK, Nov. 11, 2013 NEW YORK, Nov. 11, 2013 /PRNewswire/ -- Morgan & Morgan announces that it is...
Ryan & Maniskas, LLP Announces Investigation of Santarus, Inc. PR Newswire WAYNE, Pa., Nov. 11, 2013 WAYNE, Pa., Nov. 11, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating...
Harwood Feffer LLP Announces Investigation of Santarus, Inc. PR Newswire NEW YORK, Nov. 8, 2013 NEW YORK, Nov. 8, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating...
Santarus, Inc. and Salix Pharmaceuticals, Ltd. Merger May Not Be in Santarus, Inc. Shareholders' Best Interests PR Newswire SAN DIEGO, Nov. 8, 2013 SAN DIEGO, Nov. 8, 2013 /PRNewswire/...
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Santarus, Inc. (“Santarus” or the “Company”) (NASDAQ:SNTS) concerning the proposed acquisition of the...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of Santarus Inc. (“Santarus” or the “Company”) (NASDAQ:SNTS) related to the...
Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) is investigating the acquisition of Santarus, Inc. (NASDAQ: SNTS) by Salix Pharmaceuticals Ltd. Santarus and Salix...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
